To me the description in the Hepalink document

" Though the primary endpoint was narrowly missed, as a result of the lower than anticipated placebo event rate due to the application of new drugs, the consistent positive trend in the efficacy data suggests that RVX-208 can further decrease MACE risk on top of best available SOC"

I have underlined what to me is the important part. This is the first explanation which I have understood of the "Statistically underpowered" comments as to why the trial statistically failed to meet the required level.

I am taking Jardiance and it was one of the new drugs which my doctor prescribed for me to get my blood sugar level down. As I understand Jardiance and the other drug RVX combined with to reduce the events more than expected was not available when the company designed the study.

Thus the results in the placebo group were not as bad as initially expected since presumably more people in the placebo group ended up on Jardiance or the other drug